302440.KS
SK bioscience Co.,Ltd. [302440.KS] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
302440.KS Stock Summary
Top 10 Correlated Stocks
302440.KS
In the News
302440.KS Financial details
Company Rating
Buy
Market Cap
6165.76B
Income
278.68B
Revenue
767.28B
Book val./share
22261.89
Cash/share
-
Dividend
-
Dividend %
-
Employees
-
Optionable
No
Shortable
Yes
Earnings
06 Feb 2023
P/E
21.73
Forward P/E
-
PEG
0.37
P/S
7.89
P/B
3.54
P/C
-
P/FCF
74.19
Quick Ratio
-
Current Ratio
4.89
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
3.68K
EPS next Y
-
EPS next Q
-
EPS this Y
979.79%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-34.15%
EPS Q/Q
-54.95%
-
-
-
-
SMA20
2.35%
SMA50
-15.96%
SMA100
-29.27%
Inst Own
-
Inst Trans
-
ROA
13%
ROE
17%
ROC
0.21%
Gross Margin
62%
Oper. Margin
47%
Profit Margin
36%
Payout
-
Shs Outstand
76.78M
Shs Float
23.67M
-
-
-
-
Target Price
-
52W Range
67400.0-178500.0
52W High
-55.8%
52W Low
+17.06%
RSI
52.39
Rel Volume
0.51
Avg Volume
292.2K
Volume
148.57K
Perf Week
5.34%
Perf Month
-2.83%
Perf Quarter
-35.85%
Perf Half Y
-35.85%
-
-
-
-
Beta
-
-
-
Volatility
1662.06%, 2370.44%
Prev Close
-0.38%
Price
78900
Change
1.81%
302440.KS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2021-12-31
| Metric | History | 2021-12-31 |
|---|---|---|
| Revenue per share | 15.17K | |
| Net income per share | 5.8K | |
| Operating cash flow per share | 8.76K | |
| Free cash flow per share | 8.04K | |
| Cash per share | 26.87K | |
| Book value per share | 26.15K | |
| Tangible book value per share | 25.87K | |
| Share holders equity per share | 26.15K | |
| Interest debt per share | 1.79K | |
| Market cap | 10105.78B | |
| Enterprise value | 10113.98B | |
| P/E ratio | 28.46 | |
| Price to sales ratio | 10.88 | |
| POCF ratio | 18.83 | |
| PFCF ratio | 20.54 | |
| P/B Ratio | 6.31 | |
| PTB ratio | 6.31 | |
| EV to sales | 10.89 | |
| Enterprise value over EBITDA | 20.5 | |
| EV to operating cash flow | 18.85 | |
| EV to free cash flow | 20.55 | |
| Earnings yield | 0.04 | |
| Free cash flow yield | 0.05 | |
| Debt to equity | 0.03 | |
| Debt to assets | 0.24 | |
| Net debt to EBITDA | 0.02 | |
| Current ratio | 4 | |
| Interest coverage | 138.38 | |
| Income quality | 1.51 | |
| Dividend Yield | 0 | |
| Payout ratio | 0 | |
| Sales general and administrative to revenue | 0 | |
| Research and developement to revenue | 0.05 | |
| Intangibles to total assets | 0.01 | |
| Capex to operating cash flow | -0.08 | |
| Capex to revenue | -0.05 | |
| Capex to depreciation | -2.37 | |
| Stock based compensation to revenue | 0 | |
| Graham number | 58.4K | |
| ROIC | 0.29 | |
| Return on tangible assets | 0.17 | |
| Graham Net | 19.66K | |
| Working capital | 1377.85B | |
| Tangible asset value | 1584.25B | |
| Net current asset value | 1328.99B | |
| Invested capital | 0.07 | |
| Average receivables | 0 | |
| Average payables | 40.66B | |
| Average inventory | 102.66B | |
| Days sales outstanding | 0 | |
| Days payables outstanding | 64.93 | |
| Days of inventory on hand | 137.41 | |
| Receivables turnover | 0 | |
| Payables turnover | 5.62 | |
| Inventory turnover | 2.66 | |
| ROE | 0.22 | |
| Capex per share | -726.07 |
Quarterly Fundamentals Overview
Last date of statement is 2022-09-30 for Q3
| Metric | History | 2021-09-30 | 2021-12-31 | 2022-03-31 | 2022-06-30 | 2022-09-30 |
|---|---|---|---|---|---|---|
| Revenue per share | 2.94K | 6K | 1.14K | 1.8K | 1.19K | |
| Net income per share | 1.02K | 2.45K | 363 | 601 | 270.73 | |
| Operating cash flow per share | 779.15 | 4.49K | -1.97K | -363.64 | 129.45 | |
| Free cash flow per share | 640.11 | 4.25K | -2.28K | -788.6 | -36.47 | |
| Cash per share | 17.69K | 21.9K | 19.34K | 19.41K | 0 | |
| Book value per share | 18.9K | 21.31K | 21.33K | 21.99K | 22.26K | |
| Tangible book value per share | 18.66K | 21.08K | 21.11K | 21.76K | 22.26K | |
| Share holders equity per share | 18.9K | 21.31K | 21.33K | 21.99K | 22.26K | |
| Interest debt per share | 1.43K | 1.42K | 1.52K | 2.19K | 30.08 | |
| Market cap | 20330.67B | 16910.91B | 12026.42B | 7713.24B | 6162.92B | |
| Enterprise value | 20356.08B | 16919.11B | 11950.03B | 7734.54B | 6162.92B | |
| P/E ratio | 66.49 | 22.98 | 108.13 | 41.81 | 74.15 | |
| Price to sales ratio | 92.07 | 37.51 | 138.09 | 55.78 | 67.69 | |
| POCF ratio | 347.17 | 50.09 | -79.8 | -276.37 | 620.31 | |
| PFCF ratio | 422.58 | 52.97 | -68.99 | -127.44 | -2.2K | |
| P/B Ratio | 14.31 | 10.56 | 7.36 | 4.57 | 3.61 | |
| PTB ratio | 14.31 | 10.56 | 7.36 | 4.57 | 3.61 | |
| EV to sales | 92.18 | 37.53 | 137.21 | 55.93 | 67.69 | |
| Enterprise value over EBITDA | 199.14 | 65.71 | 304 | 123.79 | 241.83 | |
| EV to operating cash flow | 347.61 | 50.12 | -79.29 | -277.14 | 620.31 | |
| EV to free cash flow | 423.11 | 52.99 | -68.55 | -127.79 | -2.2K | |
| Earnings yield | 0 | 0.01 | 0 | 0.01 | 0 | |
| Free cash flow yield | 0 | 0.02 | -0.01 | -0.01 | 0 | |
| Debt to equity | 0.03 | 0.03 | 0.03 | 0.01 | 0 | |
| Debt to assets | 0.26 | 0.24 | 0.18 | 0.19 | 0.19 | |
| Net debt to EBITDA | 0.25 | 0.03 | -1.94 | 0.34 | 0 | |
| Current ratio | 3.7 | 4 | 5.47 | 4.7 | 4.89 | |
| Interest coverage | 122.78 | 331.33 | 31.77 | 86.94 | 9.25 | |
| Income quality | 0.77 | 1.84 | -5.42 | -0.61 | 0.48 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.01 | 0 | 0.01 | 0.01 | 0.38 | |
| Research and developement to revenue | 0.07 | 0.03 | 0.14 | 0.08 | 0 | |
| Intangibles to total assets | 0.01 | 0.01 | 0.01 | 0.01 | 0 | |
| Capex to operating cash flow | -0.18 | -0.05 | 0.16 | 1.17 | -1.28 | |
| Capex to revenue | -0.05 | -0.04 | -0.27 | -0.24 | -0.14 | |
| Capex to depreciation | -2.16 | -3.61 | -4.07 | -5.07 | -1.78 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 20.79K | 34.25K | 13.2K | 17.24K | 11.65K | |
| ROIC | 0.07 | 0.15 | 0.01 | 0.04 | 0.01 | |
| Return on tangible assets | 0.04 | 0.09 | 0.01 | 0.02 | 0.01 | |
| Graham Net | 11.95K | 16.02K | 15.52K | 15.22K | -5.09K | |
| Working capital | 1210.54B | 1377.85B | 1392.49B | 1400.71B | 1416.84B | |
| Tangible asset value | 1402.63B | 1584.25B | 1616.69B | 1669.74B | 0 | |
| Net current asset value | 1160.27B | 1328.99B | 1335.88B | 1372.79B | 1390.25B | |
| Invested capital | 0.08 | 0.07 | 0.07 | 0.1 | 0 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 41.43B | 41.1B | 17.08B | 18.38B | 0 | |
| Average inventory | 152.51B | 152.53B | 159.91B | 170.01B | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 64.85 | 34.11 | 36.16 | 31.73 | 0 | |
| Days of inventory on hand | 135.81 | 72.19 | 343.25 | 293.48 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 1.39 | 2.64 | 2.49 | 2.84 | 0 | |
| Inventory turnover | 0.66 | 1.25 | 0.26 | 0.31 | 0 | |
| ROE | 0.05 | 0.11 | 0.02 | 0.03 | 0.01 | |
| Capex per share | -139.03 | -243.95 | -308.12 | -424.96 | -165.93 |
302440.KS Frequently Asked Questions
What is SK bioscience Co.,Ltd. stock symbol ?
SK bioscience Co.,Ltd. is a KR stock and trading under the symbol 302440.KS
What is SK bioscience Co.,Ltd. stock quote today ?
SK bioscience Co.,Ltd. stock price is $78900 today.
Is SK bioscience Co.,Ltd. stock public?
Yes, SK bioscience Co.,Ltd. is a publicly traded company.
Company Profile
- Volume Average 292.2K
- Market Capitalization 6165.76B
- CEO Mr. Jae-Yong Ahn
- Headquarters Seongnam-si,KR
- IPO Date 2021-03-18
-
Website
https://www.skbioscience.co.kr 
SK bioscience Co.,Ltd. engages in the research and development, production, and distribution of vaccines and biopharmaceuticals in Korea and internationally. Its product portfolio includes Skycellflu, a cell cultured influenza surface antigen vaccine; Skycellflu 4-ga pre-filled syringe; pneumococcal vaccine for adult and infant; Skyzoster, a shingles virus vaccine; and Sky Baricella for the prevention of chickenpox infection in children. The company also engages in the development of oral rotavirus vaccine that has completed phase 2 clinical trial; cervical cancer vaccine, which has completed phase 2 clinical trial; rotavirus vaccine that is in phase 3 clinical trial in Africa; typhoid conjugate vaccine; and Corona 19 vaccine that is in phase 1 and phase 1/2 clinical trials; and low-cost pneumococcal vaccine, which has completed phase 2 clinical trial and next-generation pneumococcal vaccine that is in phase 2 clinical trial in the United States. SK bioscience Co.,Ltd. was founded in 2018 and is based in Seongnam-si, South Korea.
